Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Next Previous
Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lebrikizumab (Primary) ; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms The RIFF study
  • Sponsors Chugai Pharmaceutical; Roche

Most Recent Events

  • 19 May 2021 Results of pooled analysis CAPACITY studies (NCT00287729 and NCT00287716), and from all patients in GIPF-001 (NCT00047645) and RIFF (Cohort A) (NCT01872689) assessing change in the DLco measurements over 6-month intervals, presented at the 117th International Conference of the American Thoracic Society.
  • 02 Oct 2020 Results published in the European Respiratory Journal
  • 20 May 2020 Results of post-hoc exploratory analyses evaluating the associations for imaging features with baseline FVCpp and biomarker levels from CAPACITY-006 (NCT00287729) and RIFF (NCT01872689), presented at the 116th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top